Skip to main content

Table 1 Initial clinical characteristics

From: Prediction of left ventricular reverse remodeling after therapy with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers and β blockers in patients with idiopathic dilated cardiomyopathy

Variables LVRR (+) LVRR (−) p value
(n = 15) (n = 29)
Age (years) 60 ± 11 58 ± 13 0.512
Men 13 (87%) 26 (89%) 0.767
New York Heart Association class
I – II 11 24 0.207
III – IV 5 5  
Diabetes mellitus 4 (27%) 3 (10%) 0.206
Atrial fibrillation 6 (40%) 4 (14%) 0.067
Nonsustained ventricular tachycardia 6 (40%) 11 (38%) 0.894
Serum creatinine (mg/dl) 0.87 ± 0.16 0.81 ± 0.25 0.406
Estimated glomerular filtration rate (ml min-1 1.73 m-2) 80.3 ± 12.2 79.8 ± 12.1 0.738
Complete left bundle brunch brock 2 (13%) 6 (21%) 0.549
QRS duration (ms) 101 ± 14 111 ± 32 0.173
Follow-up periods (years) 5.9 ± 3.2 4.4 ± 2.8 0.220
Pharmacological treatments
β blockers 15 (100%) 29 (100%) >0.99
Carvedilol 13 (87%) 24 (83%) 0.737
Dose (mg/day) 11.3 ± 4.8 10.8 ± 5.3 0.761
Metoprolol 2 (13%) 5 (17%) 0.735
Dose (mg/day) 60.0 ± 28.2 56.0 ± 21.9 0.879
Angiotensin converting enzyme inhibitors/angiotensin II receptor blockers 12 / 3 (100%) 24/5 (100%) >0.99
Enalapril 10 (67%) 20 (69%) 0.877
Dose (mg/day) 5.2 ± 1.8 4.6 ± 0.9 0.318
Losartan 2 (13%) 3 (20%) 0.767
Dose (mg/day) 37.5 ± 17.7 41.7 ± 14.4 0.738
Loop diuretics 13 (87%) 27 (93%) 0.596
Spironolactone 7 (45%) 15 (52%) 0.751
Digitalis 11 (73%)’ 20 (67%) 0.763
Amiodarone 1 (7%) 4 (14%) 0.647
  1. Data are presented as mean ± SD or n (%). LVRR, left ventricular reverse remodeling.